Xenetic Biosciences Inc.

AI Score

0

Unlock

4.11
0.00 (0.00%)
At close: Jan 15, 2025, 12:29 PM
undefined%
Bid 3.94
Market Cap 6.34M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.66
PE Ratio (ttm) -1.55
Forward PE n/a
Analyst Hold
Ask 4.28
Volume 8,688
Avg. Volume (20D) 22,277
Open 4.32
Previous Close 4.11
Day's Range 3.93 - 4.32
52-Week Range 2.78 - 5.20
Beta undefined

About XBIO

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor ...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2016
Employees 4
Stock Exchange NASDAQ
Ticker Symbol XBIO

Analyst Forecast

According to 1 analyst ratings, the average rating for XBIO stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 0.00%
Hold 100.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Xenetic Biosciences Inc. is scheduled to release its earnings on Mar 20, 2025, after market closes.
Analysts project revenue of $230.00K, reflecting a -65.77% YoY shrinking and earnings per share of -0.2, making a -125.97% decrease YoY.